← Back to screener

Akari Therapeutics Plc AKTX

Rank #1058 · Nasdaq · $754.5B market cap
⚠ Going-concern flag — the auditor (BDO USA, P.C.) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
54.1
P/E
-38124.0
P/B
-3294812.92
ROE
8642.4%
Op. Margin
–%
Debt Ratio
-12372%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -38124.0x, P/B -3294812.92x. Ranks in the top 80% of the universe.

Profitability ★★★★★
Excellent

ROE 8642.4%. Ranks in the top 0% of the universe.

Safety ★★★★★
Excellent

Debt ratio -12372%. Ranks in the top 0% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014–$-0.0B$-0.0B$-0.0B–-415
2015–$-0.0B$-0.0B$0.0B–292
2023–$-0.0B$-0.0B$0.0B–217
2024–$-0.0B$-0.0B$0.0B–256
2025–$-0.0B$-0.0B$-0.0B–-12372

← See the full screener